- Home
- TRDA vs XGN Comparison
TRDA vs XGN Comparison
Compare TRDA & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- XGN
- Stock Information
- Founded
- TRDA 2016
- XGN 2002
- Country
- TRDA United States
- XGN United States
- Employees
- TRDA N/A
- XGN N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- XGN Medical Specialities
- Sector
- TRDA Health Care
- XGN Health Care
- Exchange
- TRDA Nasdaq
- XGN Nasdaq
- Market Cap
- TRDA 222.5M
- XGN 210.4M
- IPO Year
- TRDA 2021
- XGN 2019
- Fundamental
- Price
- TRDA $5.84
- XGN $11.04
- Analyst Decision
- TRDA Strong Buy
- XGN Strong Buy
- Analyst Count
- TRDA 3
- XGN 5
- Target Price
- TRDA $25.67
- XGN $12.40
- AVG Volume (30 Days)
- TRDA 350.3K
- XGN 255.7K
- Earning Date
- TRDA 11-04-2025
- XGN 11-11-2025
- Dividend Yield
- TRDA N/A
- XGN N/A
- EPS Growth
- TRDA N/A
- XGN N/A
- EPS
- TRDA N/A
- XGN N/A
- Revenue
- TRDA $79,476,000.00
- XGN $58,862,000.00
- Revenue This Year
- TRDA N/A
- XGN $22.28
- Revenue Next Year
- TRDA N/A
- XGN $14.03
- P/E Ratio
- TRDA N/A
- XGN N/A
- Revenue Growth
- TRDA N/A
- XGN 3.89
- 52 Week Low
- TRDA $4.93
- XGN $2.38
- 52 Week High
- TRDA $21.79
- XGN $11.28
- Technical
- Relative Strength Index (RSI)
- TRDA 51.80
- XGN 64.51
- Support Level
- TRDA $5.82
- XGN $10.63
- Resistance Level
- TRDA $6.90
- XGN $11.28
- Average True Range (ATR)
- TRDA 0.36
- XGN 0.38
- MACD
- TRDA 0.07
- XGN -0.00
- Stochastic Oscillator
- TRDA 45.88
- XGN 80.41
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.